source
- ADARx raises $446 million in one of 2026's largest biotech IPOs as City Therapeutics plans its own listingADARx Pharmaceuticals completed an initial public offering that raised about $446.3 million, exceeding the company’s original target. The shares were priced at $17 each, with 26.25 million shares…
- ADARx prices $446.3 million Nasdaq debut, boosting biotech IPO waveADARx Pharmaceuticals, a RNA interference focused biotech, announced pricing of its initial public offering at $446.3 million on Nasdaq. The offering was upsized, reflecting strong investor demand…